Use of real-world evidence in the U.S. Food and Drug Administration and the European Medicines Agency approvals of oncology products supported by single-arm trials (2022-2025)
RWE is increasingly used to support oncology SATs and holds promise as supportive or contextual evidence in regulatory decision-making and methodological limitations commonly included small sample sizes, population heterogeneity, missing or unmeasured covariates, non-aligned outcome assessments, post-hoc design, and no...